The upregulation of genes such as ELOVL3 and PECR in non‐lesional skin and ELOVL3 and FADS2 in plaque skin may improve lipid barrier function, suggesting that bevacizumab could potentially alleviate epidermal barrier dysfunction and limit disease progression in psoriasis. This evidence concerns the gene ELOVL3 and psoriasis.